Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Delenex Therapeutics AG Establishes Advisory Board

Published: Saturday, July 26, 2014
Last Updated: Saturday, July 26, 2014
Bookmark and Share
Renowned specialists to support development of Delenex’ advancing pipeline.

Delenex Therapeutics AG has announced the establishment of an advisory board of seasoned executives and scientists. Seven world-renowned specialists will bring strong clinical, scientific and drug formulation expertise and assist in developing and implementing Delenex R&D strategy.

The members of the advisory board are:
Michael Detmar, M.D., Professor of Pharmacogenomics at the ETH Zurich, Switzerland. Professor Detmar is Dermatologist by training; his research work has led to a fundamental understanding of angiogenesis in skin inflammatory disorders.

Peter Elias, M.D., Professor of Dermatology at the UCSF, San Francisco, CA, USA. Prof. Elias has analyzed in depth over decades the function of the stratum corneum of the skin resulting in a novel understanding on this part of the skin.

Richard Guy, Ph.D., Professor of Pharmaceutical Sciences at the University of Bath, UK. Prof. Guy’s research focuses on skin barrier function characterization, dermal drug delivery and the assessment of skin penetration.

James G. Krueger, M.D., Ph.D., Professor of Dermatology at The Rockefeller University, New York, NY, USA. Prof. Krueger has done analyses on the regulation of immune pathways in psoriatic skin.

Thomas Luger, M.D., Ph.D., Professor of Dermatology and Chairman of the Department of Dermatology, and also the Director of the Institute of Cell Biology and Immunobiology of the Skin at Münster University, Germany. Prof. Luger’s clinical interest is focused on allergic inflammation and autoimmune diseases of the skin.

Georg Stingl, M.D., Professor and Chairman of Dermatology, Division of Immunology, Allergy & Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Austria. Prof. Stingl brings extensive experience in the regulation of skin immunology by dendritic cells and in clinical development.

Gerhard Winter Ph.D., Professor of Pharmaceutical Technology and Biopharmacy at the University of Munich, Germany. Prof. Winter’s extensive expertise is in the field of formulating proteins.

Thomas Jung, CMO at Delenex, said: “I am very much looking forward to have the opportunity to work with these prestigious experts on the further development of Delenex’ pre- and clinical products”.

“We are delighted and honored to have these internationally acknowledged leaders in dermatology and skin physiology join our advisory board,” added Thomas Hecht, Delenex Therapeutics’ Executive Chairman. “Their expertise in skin immunology and physiology will be instrumental in advancing our therapeutic programs.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Delenex Announces New Pre-Clinical Data Demonstrating Anti-Tumor Activity of DLX1008
An Anti-VEGF-A antibody fragment with low picomolar affinity, in an in vivo model of Kaposi sarcoma.
Friday, May 29, 2015
Delenex Announces New Clinical Data
New clinical data show biological activity of DLX105 in patients with Behçet’s disease.
Thursday, April 16, 2015
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
How the Brain Recognizes Faces
Machine-learning system spontaneously reproduces aspects of human neurology.
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!